Format

Send to

Choose Destination
Alzheimers Dement. 2018 May;14(5):634-643. doi: 10.1016/j.jalz.2017.10.005. Epub 2017 Nov 20.

Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results.

Author information

1
Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
2
Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; Department of Psychiatry, Hospital Universitari Vall d'Hebron, CIBERSAM, Universitat Autònoma de Barcelona, Barcelona, Spain.
3
Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; Cognition and brain plasticity group [Bellvitge Biomedical Research Institute-IDIBELL], L'Hospitalet de Llobregat, Barcelona, Spain.
4
Servei de Medicina Nuclear, Hospital Clínic i Provincial, Barcelona, Spain.
5
Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain.
6
CIBERDEM-Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders, Madrid, Spain; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
7
Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain. Electronic address: aruiz@fundacioace.com.

Abstract

INTRODUCTION:

Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored.

METHODS:

We evaluated apolipoprotein E (APOE) ε4's effect in the risk of presenting SCD, using the Fundacio ACE Healthy Brain Initiative (FACEHBI) SCD cohort and Spanish controls, and performed a meta-analysis addressing the same question. We assessed the relationship between APOE dosage and brain amyloid burden in the FACEHBI SCD and Alzheimer's Disease Neuroimaging Initiative cohorts.

RESULTS:

Analysis of the FACEHBI cohort and the meta-analysis demonstrated SCD individuals presented higher allelic frequencies of APOE ε4 with respect to controls. APOE dosage explained 9% (FACEHBI cohort) and 11% (FACEHBI and Alzheimer's Disease Neuroimaging Initiative cohorts) of the variance of cerebral amyloid levels.

DISCUSSION:

The FACEHBI sample presents APOE ε4 enrichment, suggesting that a pool of AD patients is nested in our sample. Cerebral amyloid levels are partially explained by the APOE allele dosage, suggesting that other genetic or epigenetic factors are involved in this AD endophenotype.

KEYWORDS:

APOE alleles; Alzheimer's disease; Amyloid burden; PET; Subjective cognitive decline

PMID:
29156223
DOI:
10.1016/j.jalz.2017.10.005
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center